Johnson & Johnson reported stronger-than-expected adjusted earnings per share growth and maintained an optimistic outlook for the second half of the year, despite some pricing pressures and muted growth in certain segments. Management's focus on strategic acquisitions and cost-saving measures provides confidence in sustaining growth momentum, which could positively influence investor sentiment in the short term.

[1]